Journal of Geriatric Oncology - Volume 7/6 - Supplement 1 - November 2016

75 / 154

A B S T R A C T S S45
were comparable between older and younger patients, there
was a trend toward more dose reductions in the older group
(P = 0.12). The incidence of hematological toxicities did not
differ significantly between groups. The incidence of grade
3/4 diarrhea was significantly higher in the older group (P =
0.014) and hypersensitivity was significantly more frequent
in the younger group (P = 0.035). Patients 65 had equivalent
response rate, progression-free survival and overall survival
compared with those <65.
Conclusion: This retrospective analysis indicates that DC
therapy was tolerable and effective for the treatment of elderly
chemotherapy-naive patients with endometrial cancer.
Disclosure of interest: None declared
Keywords: Carboplatin, docetaxel, elderly, endometrial cancer
P016
LONG SURVIVAL OF A METASTATIC BREAST CANCER
SERIES OF ELDERLY PATIENTS IN A COMPREHENSIVE
CANCER CENTER
I. Morilla1,*, A. Stradella1, V. Navarro2, A. Rodriguez1, M. Gil1,
M. Antonio1, S. Recalde1, S. Pernas1
1Clinical Oncology, 2Clinical Trial Unit, Instituto Catalan de
Oncologia, Hospitalet de Llobregat, Spain
Introduction: New targeted therapies and cytotoxic agents
have improved overall survival (OS) in metastatic breast
cancer (MBC) patients (p), but only 20% are alive at 5 years
and median OS is 20m. This improvement in overall survival
occurs mainly in younger p. Elderly p are underrepresented
in clinical trials and because evidence is scarce in this
population, they are usually under-treated. About 80% of
MBC in elderly p is hormone receptor (HR)-positive and HER-
2 negative. Hormonal therapy (HT) is the mainstay in the
majority of theses p, but in endocrine refractory tumors or
triple negative, chemotherapy (CT) is the unique option, a part
from best supportive care (BSC). CT toxicities limit its use in
the elderly and individualized assessment is needed.
Objectives: The aim of our study was to describe the clinical
characteristics and survival of elderly p with MBC in a single
cancer comprehensive center.
Methods: Ambispective analysis of elderly p, defined as
70 years, with MBC with active treatment or BSC at Catalan
Institute of Oncology (ICO-Barcelona) between March 2014
and May 2016. Baseline patient and tumor characteristics
and treatments received were collected. Median overall
survival (OS) were obtained with the Kaplan-Meier method
and compared with LogRank test. The association of clinic-
pathological variables and outcome was studied by Cox
proportional hazard analysis.
Results: Out of 80 p, 49 (61.5%) were diagnosed at de novo
IV stage. Median age of MBC diagnosis was 77y (72-82). 63p
(78.8%) had RH-positive: 33p (41.3%) luminal A-like and 30p
(37.5%) luminal B-like (St Galen 2013 definition), 7p (11.3%)
were HER2-positive and 8p (10%) triple negative (TN). Grade 1
(G1):2.5%, G2: 41.3% and G3: 23.8%. Sites of metastasis: Bone
55p (69%), lymph nodes 23p (29%), skin lesions 19p (24%),
lung-pleura 19p (24%), liver 14p (17.5%) and central nervous
system 2p (2.5%). 58p (73%) with HR-positive received at least
one line of hormonal treatment (52% just one line and 48%
1 line of HT). Letrozol was the most used HT in 51p, in 19p
(24%) p was the only treatment received. Tamoxifen was
the most common 2nd line HT 24p (30%). 47p (59%) received
chemotherapy, 22 (27.5%) were treated with one line, 9 (11.3%)
two lines, 5 (6.3%) three lines and 4 (5%) four lines. Weekly
paclitaxel was prescribed in 43(53%), capecitabine 40 (50%)
and vinorelbine 32 (40%). 25 (31%) received chemotherapy
following HT. Only 2 p (2.5%) were enrolled in a clinical trial.
Median OS from initial diagnosis of BC was 183m (81-285) with
a statistically significant difference according to histological
subtypes: Luminal A-like 252m, Luminal B-like 164m, TN 24m
and Her2 NR (p= 0.04). Overall survival after MBC diagnosis
was 60.4 m: Luminal A-like 61m, Luminal B-like 43m, TN 22m,
Her-2 NR (p= 0.08).
Conclusion: OS after MBC diagnosis was 60.4 m in our
series of elderly p; this OS exceeds the data in the literature,
as more luminal A-like tumors were included. Notably,
61.5% were diagnosed at de novo IV stage, probably because
p70y are not included in screening programs and some are
reluctant to go to the doctor. Only 2 p (2.5%) were enrolled in a
clinical trial. A special effort must be made to include elderly
patients in clinical trials.
Disclosure of interest: None declared
Keywords: Elderly patients, metastatic breast cancer
P017
IL-6 SECRETION REDUCTION IN ELDERLY PATIENTS
UNDERGOING ELECTIVE COLORECTAL LAPAROSCOPIC
SURGERY UNDER ERAS. RESULTS FROM A RANDOMIZED
CLINICAL TRIAL
A. Costanzi1,*, G. Mari1, J. Crippa1, A. Miranda1, A. Rosato1,
V. Berardi1, D. Maggioni1
1General Surgery, Desio Hospital, Desio, Italy
Introduction: Enhanced Recovery After Surgery program
applied to colorectal laparoscopic surgery is well known
to reduce hospitalization improving short terms outcomes
and minimizing the Surgical Stress Response. However its
effectiveness in elderly population is yet to be demonstrated.
Objectives: The primary aim of this study is to compare
the level of immune and nutritional serum indexes across
surgery in patients aged over 70 years old undergoing elective
colorectal laparoscopic surgery within an ERAS protocol or
according to a Standard of Care program.
Methods: 80 patients undergoing major colorectal laparo-
scopic surgery were enrolled and randomized in two groups
(40 per arm) within a larger randomized trial on a general
population. Cortisol, C Reactive Protein, White Blood Cell
Count, Prolactin, IL-6 levels were collected preoperatively, 1, 3
and 5 days after surgery.Transferrin, Prealbumin,Albumin and
Triglyceride level were collected preoperatively, 1 and 5 days
after surgery. Short Term Outcomes were also prospectively
assessed.